Data and evidence tailored to your questions
We match the data, insights, and delivery method to your priorities.
Point of diagnosis insights
Surface eligible candidates in near real time, weeks before genomic testing, EHR, or claims alone.
Multimodal data
Access rich profiles that match pathology images, molecular, clinical, and genomic data.
Network-enabled actions
Run additional testing, generate new data, and alert physicians through a diverse diagnostic network.
Real time data from a diverse diagnostic network
Aperture is powered by a global network of diagnostic laboratories who use Concentriq, our pathology AI platform, every day for routine diagnosis across therapeutic areas.
This embedded position enables real-time engagement within routine diagnostic workflows—supporting tailored testing, new data generation, and timely action. It also gives you access to targeted, structured insights on biomarker- or disease-defined populations weeks or months before they appear in downstream datasets.
16M+
Unique patient records managed by and available in Aperture
4,000+
Hospitals and clinics, growing daily
150+
Unique biomarkers including standard-of-care and emerging
“Too many patients never have the chance to benefit from breakthrough therapies. Pathology data holds the keys to changing this. By unlocking insights at the moment of diagnosis, we can ensure that researchers have the understanding they need to bring the next therapies to market while giving patients a greater opportunity to access them.”
Discover biomarkers. Enroll faster. Expand access.
We match the data, insights, and delivery method to your evidence priorities.
Discovery & translational
Use multimodal data to uncover novel biomarkers, identify new targets, and build AI-based diagnostics for patient stratification and treatment response.
Clinical development
Model disease and biomarker prevalence to identify eligible candidates at diagnosis, activate high-volume providers, and onboard high-performing sites for faster enrollment.
Commercial
Expand access by driving provider engagement, identifying treatment delays, and generating real-world evidence that supports regulatory submissions, CDx strategy, and label expansions.
